DUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN) today provides an update on ELND005 (Scyllo-inositol). Elan has entered into a manufacturing agreement for the supply of the active pharmaceutical ingredient for ELND005 with Lonza Group AG. This agreement is fundamental to ensuring that a high quality supply of ELND005 will be available to support the advancement of the program.
